Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer

Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient’s Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis

“…The clinical outcomes of NAT are closely related to therapeutic plans. A retrospective study assessed efficacy and safety of nanoparticle albumin-bound paclitaxel-based chemotherapy (nPBC) and docetaxel-based chemotherapy (DBC) as NAT for breast cancer, revealing that nPBC is correlated with favorable pCR [39]. We analyzed patients with main biological subtypes of breast cancer (HER2-positive breast cancer and TNBC).…”

Efficacy and Safety of Albumin-bound Paclitaxel Versus Solvent-based Paclitaxel in Breast Cancer: A Meta-analysis

“…Of 304 original papers retrieved by an electronic search, 233 papers were excluded after literature abstracts reading and exclusion of case reports, abstracts, reviews, and single-arm research, and 71 papers were coarsely included. Studies with duplicate reports, unspecified data, subgroup analyses, and post hoc analyses were further ruled out, and the final 13 pieces (comprising 4252 patients) of literature were recruited [16][17][18][19][20][21][22][23][24][25][26][27][28] , in which 9 studies [18][19][20][21][24][25][26][27][28] adopted neoadjuvant chemotherapy and 4 adopted conventional chemotherapy [16,17,22,23] for breast cancer. The basic information of the included literature is shown in Table 1, and the quality evaluation of the included literature is shown in Figure 1.…”

“…The basic information of the included literature is shown in Table 1, and the quality evaluation of the included literature is shown in Figure 1. Kuwayama et al [20] 2018 Phase II Stage I-III BC HER2-Negative NAC 77 75 pCR, ORR, AEs Xie et al [21] 2018 Retrospective Operable early BC Undistinguished NAC 79 83 pCR, AEs Guan et al [22] 2019 Phase II Metastatic BC Undistinguished RC 104 106 ORR Tamura et al [23] 2017 Phase II Metastatic BC HER2-Negative RC 98 99 ORR Huang et al [24] 2015 Phase II Locally advanced BC Undistinguished NAC 90 30 pCR, ORR, AEs Chen et al [25] 2021 Phase II Stage II-III BC Undistinguished NAC 63 41 pCR, ORR, AEs Lv et al [26] 2022 Retrospective Stage II-III BC HER2-negative NAC 80 79 pCR, ORR, AEs Yang et al [27] 2019 Retrospective Stage II-III BC HER2-negative NAC 25 25 pCR, AEs Li et al [28] 2021 Retrospective Metastatic BC HER2-positive NAC 97 104 pCR, AEs…”

“…The use of Sb-PTX and Nab-PTX in neoadjuvant chemotherapy was compared in nine papers, all of which reported pCR [18][19][20][21][24][25][26][27][28] , and six papers reported ORR [18][19][20][24][25][26] . The pCR was 0.163 (95% CI: 0.098-0.227) after Sb-PTX treatment and 0.280 (95% CI: 0.218-0.341) after Nab-PTX treatment (I 2 =31%, P=0.17).…”

“…Peripheral sensory neuropathy (PSN) is a common adverse effect of paclitaxel, which is associated with discont-inuation of therapy, impaired treatment outcome, and compromised quality of life of patients. In the present study, eight papers investigated the incidence of PSN in Sb-PTX and Nab-PTX, of which seven reported the incidence of all grade-PSN [18][19][20][24][25][26][27] and six reported the incidence of grade≥3 PSN [18,19,[24][25][26][27] . The incidence of all grade-PSN was 0.392 (95% CI: 0.243-0.541) for Sb-PTX therapy and 0.591 (95% CI: 0.452-0.729) for Nab-PTX therapy (I 2 =60%, P=0.02).…”